The “five-star matrix” for patient-centric drug discovery and development in neuroscience
Neuron · 2025-09 · 113 (18) · 2885-2909
DOI: 10.1016/j.neuron.2025.08.004 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Neuron, 2025-09. Verfasst von Axel Pähler und 11 weiteren Autor:innen. Beteiligte Einrichtung: Pharma Research and Early Development, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd, 4070 Basel, Switzerland. Electronic address: axel.pae…. Hauptthemen laut MEDLINE: Drug Discovery, Neurosciences, Drug Development, Translational Research, Biomedical. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 226 Literaturangaben. Gefördert von: Roche.
Abstract (Originalsprache)
Progress in understanding human biology has revealed potential therapeutic targets for brain disorders. Yet, the discovery of new neuroscience drugs is often hampered by the lack of precise translation tools and disease models, resulting in high preclinical and clinical failure rates. To improve success, robust translational foundations linking pharmacological targets to disease phenotypes are essential. The "five-star matrix" offers a comprehensive framework for translational drug discovery, consisting of five "dimensions" (biodistribution, target binding/occupancy, proximal effect, biological effect, and disease effect) and five "systems" (biochemical, cellular, ex vivo, preclinical, and clinical). By identifying translatable biomarkers across these dimensions and systems, researchers can test hypotheses from early target assessments to clinical studies. Although linking pathogenic processes to disease-relevant endpoints is challenging, applying the five-star matrix across neuroscience projects fosters collaboration to develop holistic, patient-centric strategies with clear deliverables toward clinical proof of concept. Case studies illustrate the rationale for the five-star matrix in creating a translational continuum from bench to bedside.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Pharma Research and Early Development, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd, 4070 Basel, Switzerland. Electronic address: axel.paehler@roche.com.
- Pharma Research and Early Development, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd, 4070 Basel, Switzerland.
- Pharma Research and Early Development, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd, 4070 Basel, Switzerland. Electronic address: antonia.stepan@roche.com.
Förderung
- Roche
Zitieren
APA
Pähler, A., O'Connor, E. C., Binch, H., Dudal, S., Gobbi, L. C., Lübbers, T., Olivares-Morales, A., Rodríguez Sarmiento, R. M., Grether, U., Stahl, M., Pagano, G., & Stepan, A. F. (2025). The “five-star matrix” for patient-centric drug discovery and development in neuroscience. Neuron, 113(18), 2885-2909. https://doi.org/10.1016/j.neuron.2025.08.004
Vancouver
Pähler A, O'Connor EC, Binch H, Dudal S, Gobbi LC, Lübbers T, et al. The “five-star matrix” for patient-centric drug discovery and development in neuroscience. Neuron. 2025;113(18):2885-2909. doi:10.1016/j.neuron.2025.08.004
BibTeX
@article{Phler2025,
author = {Pähler, Axel and O'Connor, Eoin C and Binch, Hayley and Dudal, Sherri and Gobbi, Luca C and Lübbers, Thomas and Olivares-Morales, Andrés and Rodríguez Sarmiento, Rosa María and Grether, Uwe and Stahl, Martin and Pagano, Gennaro and Stepan, Antonia F},
title = {The “five-star matrix” for patient-centric drug discovery and development in neuroscience},
journal = {Neuron},
year = {2025},
volume = {113},
number = {18},
pages = {2885--2909},
doi = {10.1016/j.neuron.2025.08.004}
}
EUVIMED